IBJNews

Lilly's insulin dip concerns analysts

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. suffered a tough week on the stock market, in part because of a disturbing bit of news buried in its third-quarter earnings report: Lilly’s insulin sales are down.

The Indianapolis-based drugmaker is relying heavily on sustaining $3.5 billion in annual sales of its Humulin and Humalog insulins to carry it through its current string of patent expirations on other drugs—at least until it can launch new drugs to pick up the slack.

But in the third quarter, sales of Humalog fell 3 percent and sales of Humulin fell 5 percent, compared with the same quarter a year ago. Lilly officials said they lost share in the insulin market in the first half of the year, although the situation has stabilized now.

Still, those problems sparked a lot of questions from Wall Street analysts during a conference call Oct. 24. And Lilly’s share price slipped 3 percent from its close on Oct. 23 until the end of the week. The stock closed Friday at $50.26 per share.

“The Humalog and Humulin sales were light relative to our expectations,” noted Goldman Sachs analyst Jami Rubin during the conference call with Lilly executives. She added, “Insulin scripts have been strong. So what’s happening with the pricing environment?”

Both Humalog and Humulin suffered because they were removed from the formulary of a large third-party payer this year, Lilly reported. Also, the contract between Lilly and Wal-Mart to use Humulin for Wal-Mart’s ReliOn brand was terminated.

But in addition to those things, Lilly officials said, third-party payers are more aggressively threatening to remove or de-emphasize each drugmaker’s insulins from their formularies if the drugmakers don’t offer better prices.

“The negotiations that we basically have with some of the major payers are more difficult. And we have seen their leverage increase as they have the ability to be able to move share as they restrict access to products given the contracts that they're able to establish,” said Enrique Conterno, president of Lilly’s diabetes unit. “So, yes, there is some pressure.”

And in addition to that, doctors are prescribing insulin later to diabetics because they first try to control blood sugar with a relatively new class of oral medicines called DPP-4s, such as Januvia and Tradjenta, and through injectible medicines known as GLP-1s, such as Byetta, Bydureon and Victoza.

“To some extent, that is delaying the initiation on insulin and some of the earlier use of insulin,” Conterno said. “We believe that some of these impacts are more short term. I think we saw similar impacts when, for example, metformin was introduced in the U.S. many years ago. So my sense is that we will continue to see long-term insulin growth rates that are much more aligned with historical rates. But we are seeing some depressed rates now.”

Lilly’s overall results in the third-quarter were “ho-hum,” according to one analyst. The company lowered its full-year profit forecast by 4 cents per share.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Why should I a home owner pay for this"car sharing" ????

  2. By the way, the right to work law is intended to prevent forced union membership, not as a way to keep workers in bondage as you make it sound, Italiano. If union leadership would spend all of their funding on the workers, who they are supposed to be representing, instead of trying to buy political favor and living lavish lifestyles as a result of the forced membership, this law would never had been necessary.

  3. Unions once served a noble purpose before greed and apathy took over. Now most unions are just as bad or even worse than the ills they sought to correct. I don't believe I have seen a positive comment posted by you. If you don't like the way things are done here, why do you live here? It would seem a more liberal environment like New York or California would suit you better?

  4. just to clear it up... Straight No Chaser is an a capella group that formed at IU. They've toured nationally typically doing a capella arangements of everything from Old Songbook Standards to current hits on the radio.

  5. This surprises you? Mayor Marine pulled the same crap whenhe levered the assets of the water co up by half a billion $$$ then he created his GRAFTER PROGRAM called REBUILDINDY. That program did not do anything for the Ratepayors Water Infrastructure Assets except encumber them and FORCE invitable higher water and sewer rates on Ratepayors to cover debt coverage on the dough he stole FROM THE PUBLIC TRUST. The guy is morally bankrupt to the average taxpayer and Ratepayor.

ADVERTISEMENT